All In Biotech

Drug Trial Radar · NCT00361881

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

A Randomized, Double-Blind, Active Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis

Last checked: Nov 19, 2026Latest source record: Aug 18, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,443 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,443

Actual

Start

Jul 2006

Primary completion

Aug 2007

Study completion Dec 2007

Sponsor

Lead sponsor
MedivirIndustry
Sponsor type
Industry
First posted
Aug 9, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.

Conditions

  • Herpes Labialis

Interventions

  • ME-609Drug

    Cream, dose 5 times daily during 5 days.

  • acyclovir in ME-609 vehicleDrug

    Dose 5 times daily for 5 days

  • VehicleDrug

    Dose 5 times daily for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with non-ulcerative recurrences measured as the proportion of subjects in whom the study recurrence did not progress beyond the papule stage.Time frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Coastal Caroline Research Center

    Mt. Pleasant, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.